- Home
- HAFN vs APLS Comparison
HAFN vs APLS Comparison
Compare HAFN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | APLS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HAFN | APLS |
|---|---|---|
| Price | $6.67 | $18.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $31.89 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.21% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.97 |
| P/E Ratio | ★ $11.39 | $91.93 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $3.61 | $16.10 |
| 52 Week High | $7.96 | $30.48 |
Technical Indicators
Market Signals| Indicator | HAFN | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 29.92 |
| Support Level | $6.01 | $16.89 |
| Resistance Level | $7.96 | $20.42 |
| Average True Range (ATR) | 0.24 | 0.92 |
| MACD | -0.15 | -0.21 |
| Stochastic Oscillator | 8.36 | 8.23 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.